NCT05124912: REMASTer: REcurrent Brain Metastases After SRS Trial

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Not Applicable
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have a “targetable” lesion in the brain that is a minimum 1.5 cm & demonstrates a 25% or greater increase in size following stereotactic radiosurgery (SRS)
Exclusions: Patients with greater than 3 progressing lesions at time of enrollment – see trial for details; Patients ineligible or unable to tolerate stereotactic radiosurgery (SRS)

Comments are closed.

Up ↑